These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33916984)

  • 1. Functional Roles of SPINK1 in Cancers.
    Lin TC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of serine protease inhibitor kazal type 1 predicts poor prognosis and promotes the progression and invasion of oral tongue squamous cell carcinoma.
    Wang S; Sun Y; Shao D; Pan Y; Gao X; Zhao P; Liu Q; Shang G; Shang W; Fu Z; Sun Y
    Arch Oral Biol; 2024 Aug; 164():106003. PubMed ID: 38781741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
    Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
    Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
    Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
    BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
    Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
    Ohmuraya M; Yamamura K
    Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
    Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
    Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
    Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
    Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
    Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
    Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
    Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
    Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Roles of SPINK1 in Cancer.
    Räsänen K; Itkonen O; Koistinen H; Stenman UH
    Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.
    Buchholz I; Nagel F; Klein A; Wagh PR; Mahajan UM; Greinacher A; Lerch MM; Mayerle J; Delcea M
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140281. PubMed ID: 31525466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine protease inhibitor Kazal type 1 mutations and pancreatitis.
    Schneider A
    Gastroenterol Clin North Am; 2004 Dec; 33(4):789-806. PubMed ID: 15528018
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lin TC
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
    Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
    Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TATI as a biomarker.
    Itkonen O; Stenman UH
    Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of SPINK1-positive prostate cancer.
    Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
    Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.